---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030661"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:43:47.305114+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics appoints Graff President, Iglesias CMO, Høiland Advisor to advance stenoparib

## Summary
- Jeremy Graff, Ph.D., named President & CDO; base salary $475K, RSUs $250K, signing bonus $75K.
- Jose Iglesias, M.D., appointed Consultant CMO; led Phase III Abraxane development at Celgene.
- Jesper Høiland, former President of Novo Nordisk U.S., joins as Strategic Advisor for commercial strategy.
- Appointments target accelerating stenoparib, a dual PARP/Tankyrase inhibitor, for advanced ovarian cancer.
- Graff previously consulted for Allarity since Dec 2023; brings 25+ years pharma experience including 17 at Eli Lilly.

## SEC filing metadata
- accession: 0001437749-24-030661
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/0001437749-24-030661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/allr20241002_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030661
- JSON: https://secwatch.observer/filing/0001437749-24-030661.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030661.txt

## Key facts
- Executive change
  Jeremy R. Graff was appointed as President and Chief Development Officer at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Development Officer
  source text: On October 3, 2024, Allarity Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy R. Graff, as the President and Chief Development Officer of the Company effective as of September 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/0001437749-24-030661-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.